{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:04:19Z","timestamp":1773342259371,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00228-026-04008-8","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:58:58Z","timestamp":1771041538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Levetiracetam in critically ill patients with augmented renal clearance: a systematic review"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1521-8121","authenticated-orcid":false,"given":"Alba Mar\u00eda","family":"Fern\u00e1ndez Varela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3266-0121","authenticated-orcid":false,"given":"Luis","family":"Ramudo Cela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"3","key":"4008_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.12793\/tcp.2018.26.3.111","volume":"26","author":"AJ Atkinson Jr","year":"2018","unstructured":"Atkinson AJ Jr (2018) Augmented renal clearance. Transl Clin Pharmacol 26(3):111\u2013114. https:\/\/doi.org\/10.12793\/tcp.2018.26.3.111","journal-title":"Transl Clin Pharmacol"},{"issue":"10","key":"4008_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101690","volume":"13","author":"I Bilbao-Meseguer","year":"2021","unstructured":"Bilbao-Meseguer I, Barrasa H, As\u00edn-Prieto E, Alarcia-Lacalle A, Rodr\u00edguez-Gasc\u00f3n A, Maynar J, S\u00e1nchez-Izquierdo J\u00c1, Balziskueta G, Griffith MS, Quilez Trasobares N, Solin\u00eds M\u00c1, Isla A (2021) Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal oraugmented renal function. Pharmaceutics 13(10):1690. https:\/\/doi.org\/10.3390\/pharmaceutics13101690","journal-title":"Pharmaceutics"},{"issue":"9","key":"4008_CR3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","volume":"57","author":"I Bilbao-Meseguer","year":"2018","unstructured":"Bilbao-Meseguer I, Rodr\u00edguez-Gasc\u00f3n A, Barrasa H, Isla A, Solin\u00eds M\u00c1 (2018) Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet 57(9):1107\u20131121. https:\/\/doi.org\/10.1007\/s40262-018-0636-7","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4008_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ane.12437","volume":"133","author":"HA Gefroh-Grimes","year":"2016","unstructured":"Gefroh-Grimes HA, Gidal BE (2016) Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. Acta Neurol Scand 133(1):4\u201316. https:\/\/doi.org\/10.1111\/ane.12437","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"4008_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/OMA.0b013e32833e996c","volume":"23","author":"AO Rossetti","year":"2010","unstructured":"Rossetti AO, Stupp R (2010) Epilepsy in brain tumor patients.\u00a0Curr Opin Neurol. 23(6):603\u2013609. https:\/\/doi.org\/10.1097\/OMA.0b013e32833e996c","journal-title":"Opini\u00f3n Actual En neurolog\u00eda"},{"key":"4008_CR6","unstructured":"Manual de Pr\u00e1ctica Cl\u00ednica en Epilepsia Recomendaciones diagn\u00f3stico-terap\u00e9uticas de la SEN (2019) Editores: Francisco Javier L\u00f3pez-Gonz\u00e1lez, Vicente Villanueva, Merc\u00e9 Falip, Manuel Toledo, Dulce Campos y Jos\u00e9 Serratosa"},{"issue":"10","key":"4008_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1592\/phco.31.10.934","volume":"31","author":"DD Spencer","year":"2011","unstructured":"Spencer DD, Jacobi J, Juenke JM, Fleck JD, Kays MB (2011) Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. Pharmacotherapy 31(10):934\u2013941. https:\/\/doi.org\/10.1592\/phco.31.10.934","journal-title":"Pharmacotherapy"},{"issue":"1","key":"4008_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2066-1","volume":"22","author":"S Farrokh","year":"2018","unstructured":"Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA (2018) Antiepileptic drugs in critically ill patients. Crit Care 22(1):153. https:\/\/doi.org\/10.1186\/s13054-018-2066-1","journal-title":"Crit Care"},{"issue":"1s","key":"4008_CR9","doi-asserted-by":"publisher","first-page":"149s","DOI":"10.18433\/jpps30081","volume":"21","author":"D Jarvie","year":"2018","unstructured":"Jarvie D, Mahmoud SH (2018) Therapeutic Drug Monitoring of Levetiracetam in Select Populations. J PharmPharmSci. 21(1s):149s\u2013176s. https:\/\/doi.org\/10.18433\/jpps30081","journal-title":"J PharmPharmSci."},{"key":"4008_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.seizure.2021.04.017","volume":"89","author":"M Nagano","year":"2021","unstructured":"Nagano M, Tagami T, Kaneko J, Kondo M, Hotta M, Kubota M, Sugaya K, Takase H, Kuno M, Unemoto K (2021) Blood concentration of Levetiracetam after bolus administration in patients with status epilepticus. Seizure 89:41\u201344. https:\/\/doi.org\/10.1016\/j.seizure.2021.04.017","journal-title":"Seizure"},{"issue":"3","key":"4008_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1528-1167.2008.01889.x","volume":"50","author":"JW Uges","year":"2009","unstructured":"Uges JW, van Huizen MD, Engelsman J, Wilms EB, Touw DJ, Peeters E, Vecht CJ (2009) Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia 50(3):415\u201321. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01889.x","journal-title":"Epilepsia"},{"key":"4008_CR12","doi-asserted-by":"publisher","DOI":"10.3171\/FOC.2008.25.10.E3","author":"KE Jones","year":"2008","unstructured":"Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, Stippler M, Fischer M, Sauber-Schatz EK, Fabio A, Darby JM, Okonkwo DO (2008) Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus. https:\/\/doi.org\/10.3171\/FOC.2008.25.10.E3","journal-title":"Neurosurg Focus"},{"issue":"9","key":"4008_CR13","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1080\/00498254.2020.1746981","volume":"50","author":"E Karatza","year":"2020","unstructured":"Karatza E, Markantonis SL, Savvidou A, Verentzioti A, Siatouni A, Alexoudi A, Gatzonis S, Mavrokefalou E, Karalis V (2020) Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. Xenobiotica 50(9):1090\u20131100. https:\/\/doi.org\/10.1080\/00498254.2020.1746981","journal-title":"Xenobiotica"},{"key":"4008_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ."},{"key":"4008_CR15","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"issue":"2","key":"4008_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12028-013-9837-y","volume":"19","author":"AM Cook","year":"2013","unstructured":"Cook AM, Arora S, Davis J, Pittman T (2013) Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient. Neurocrit Care 19(2):210-4. https:\/\/doi.org\/10.1007\/s12028-013-9837-y","journal-title":"Neurocrit Care"},{"issue":"5","key":"4008_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40262-020-00979-8","volume":"60","author":"FB Sime","year":"2021","unstructured":"Sime FB, Roberts JA, Jeffree RL, Pandey S, Adiraju S, Livermore A, Butler J, Parker SL, Wallis SC, Lipman J, Cotta MO (2021) Population pharmacokinetics of Levetiracetam in patients with traumatic brain injury and subarachnoid hemorrhage exhibiting augmented renal clearance. Clin Pharmacokinet 60(5):655-664. https:\/\/doi.org\/10.1007\/s40262-020-00979-8","journal-title":"Clin Pharmacokinet"},{"key":"4008_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcrc.2021.04.013","volume":"64","author":"CLJ Ong","year":"2021","unstructured":"Ong CLJ, Goh PSJ, Teo MM, Lim TP, Goh KKK, Ang XY, Lim LJK, Jamaludin NHB, Ang BT, Kwa LHA (2021) Pharmacokinetics of levetiracetam in neurosurgical ICU patients. J Crit Care 64:255-261. https:\/\/doi.org\/10.1016\/j.jcrc.2021.04.013","journal-title":"J Crit Care"},{"issue":"1","key":"4008_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-022-00611-w","volume":"10","author":"I Bilbao-Meseguer","year":"2022","unstructured":"Bilbao-Meseguer I, Barrasa H, Rodr\u00edguez-Gasc\u00f3n A, As\u00edn-Prieto E, Maynar J, S\u00e1nchez-Izquierdo J\u00c1, Solin\u00eds M\u00c1, Isla A (2022) Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study. J Intensive Care 10(1):21. https:\/\/doi.org\/10.1186\/s40560-022-00611-w","journal-title":"J Intensive Care"},{"issue":"1","key":"4008_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03515-w","volume":"24","author":"AM Cook","year":"2024","unstructured":"Cook AM, Hall K, Kolpek JH, Morbitzer KA, Jordan JD, Rhoney DH (2024) Enhanced renal clearance impacts levetiracetam concentrations in patients with traumatic brain injury with and without augmented renal clearance. BMC Neurol 24(1):12. https:\/\/doi.org\/10.1186\/s12883-023-03515-w","journal-title":"BMC Neurol"},{"issue":"7","key":"4008_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/10600280231202246","volume":"58","author":"SS Harlan","year":"2024","unstructured":"Harlan SS, Philpott CD, Keegan SP, Droege ME, Karve AS, Foreman B, Wakefield D, Mueller EW, Sangha K, Ngwenya LB, Courter JD, Desai P, Droege C (2024) Pharmacokinetics of levetiracetam seizure prophylaxis in severe traumatic brain injury. Ann Pharmacother 58(7):705-714. https:\/\/doi.org\/10.1177\/10600280231202246","journal-title":"Ann Pharmacother"},{"key":"4008_CR22","unstructured":"Technical Data Sheet Levetiracetam [Online]. Available at: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/75531\/FT_75531.html. Accessed on 11 Oct 2023."},{"issue":"3","key":"4008_CR23","doi-asserted-by":"publisher","DOI":"10.51987\/evidencia.v25i4.7024","volume":"25","author":"A Ciapponi","year":"2022","unstructured":"Ciapponi A (2022) Herramientas ROBINS para evaluar el riesgo de sesgo de estudios no aleatorizados. Evid Act Pract Ambul 25(3):e007024. https:\/\/doi.org\/10.51987\/evidencia.v25i4.7024","journal-title":"Evid Act Pract Ambul"},{"key":"4008_CR24","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"7","key":"4008_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, Edwards S, Ensom MH, Foster DR, Hardy B, Kiser TH, la Porte C, Roberts JA, Shulman R, Walker S, Zelenitsky S, Moher D (2015) Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet 54(7):783\u201395. https:\/\/doi.org\/10.1007\/s40262-015-0236-8","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"4008_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jcph.70007","volume":"65","author":"M Kharouba","year":"2025","unstructured":"Kharouba M, Aboelezz A, Kung JY, Mahmoud SH (2025) The impact of augmented renal clearance on the pharmacokinetics of levetiracetam in critically ill patients: a literature review. J Clin Pharmacol 65(7):815\u2013834. https:\/\/doi.org\/10.1002\/jcph.70007","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4008_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/FTD.0000000000000731","volume":"42","author":"MO Cotta","year":"2020","unstructured":"Cotta MO, Abdul-Aziz MH, Frey OR, Sime FB, Roberts JA, Roehr AC (2020) What are the predictors for achieving therapeutic levetiracetam serum concentrations in adult neurological patients? Ther Drug Monit 42(4):626\u2013630. https:\/\/doi.org\/10.1097\/FTD.0000000000000731","journal-title":"Ther Drug Monit"},{"issue":"5","key":"4008_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/FTD.0000000000000550","volume":"40","author":"N Alzueta","year":"2018","unstructured":"Alzueta N, Ortega A, Aldaz A (2018) Influence of sex, age, and weight on levetiracetam pharmacokinetics. Ther Drug Monit 40(5):628\u2013634. https:\/\/doi.org\/10.1097\/FTD.0000000000000550","journal-title":"Ther Drug Monit"},{"issue":"3","key":"4008_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9030036","volume":"16","author":"SH Mahmoud","year":"2017","unstructured":"Mahmoud SH, Shen C (2017) Augmented renal clearance in critical illness: an important consideration in drug dosing. Pharmaceutics 16(3):36. https:\/\/doi.org\/10.3390\/pharmaceutics9030036","journal-title":"Pharmaceutics"},{"issue":"3","key":"4008_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/phar.2231","volume":"39","author":"AM Cook","year":"2019","unstructured":"Cook AM, Hatton-Kolpek J (2019) Augmented renal clearance. Pharmacotherapy 39(3):346\u2013354. https:\/\/doi.org\/10.1002\/phar.2231","journal-title":"Pharmacotherapy"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04008-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04008-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04008-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:54:32Z","timestamp":1773309272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04008-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4008"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04008-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}